VIICTR Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
View in:
PubMed
subject areas
Adenocarcinoma
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Area Under Curve
Brain Neoplasms
Carboplatin
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Chemoradiotherapy
Disease Progression
Disease-Free Survival
Drug Administration Schedule
ErbB Receptors
Erlotinib Hydrochloride
Feasibility Studies
Female
Humans
Lung Neoplasms
Male
Middle Aged
Mutation
Paclitaxel
Prospective Studies
Protein Kinase Inhibitors
Quinazolines
Radiotherapy, Intensity-Modulated
Time Factors
authors with profiles
RITSUKO KOMAKI
GEORGE R BLUMENSCHEIN
IGNACIO IVAN WISTUBA
JAMES WELSH
JIUN-KAE JACK LEE